Hospital acquired Disease Testing – Hospital or Mortuary
Hospital acquired disease or nosocomial infection is a localized or systemic condition in patients occurred due to adverse reaction caused by infectious toxin agents under medical care and were absent at the time of admission. Hospitals acquired infections results in prolonged hospital stay, antimicrobial resistance, long-term disabilities, and increase mortality rate. Pathogens responsible for nosocomial infections include viruses, fungal parasites, and bacteria.
Request a sample copy of this report:https://www.coherentmarketinsights.com/insight/request-sample/992
Hospital acquired infection is emerging as a major burden for society, patients, and healthcare management
Hospital acquired disease could be catheter-related blood stream infection, surgical site infection, ventilator-associated pneumonia, and catheter-associated urinary tract infection. These infection occurring in emerging economies globally. According Asia Pacific Journal of Tropical Medicine, 2017, Nosocomial infections account for around 10% in emerging economies and around 7% in developed economies out of all the infections. According to the World Health Organization (WHO), 2011, approximately around 15% patients hospitalized suffer from above mentioned infections, due to exposure to pathogens through different sources, such as healthcare staff and infected patients. Newborns, especially in emerging economies are also at high risk to develop hospital acquired infection. According to WHO, 2011, the infection rate in newborns is 20 times higher in emerging economies as compared to high income economies.
Hospital acquired infection is emerging as a major burden for society, patients, and healthcare management. Nosocomial infections could be prevented by practicing infection control programs and adopting antimicrobial control policies. For instance, National Health & Medical Research Council Australia (NHMRC), 2002 provided critical guidelines for the management of infections, prevention, and control in healthcare organizations.
The global hospital acquired disease testing market was valued at US$ 539 million in 2016 and is expected to witness a robust CAGR of 19.70% over the forecast period (2017 – 2025).
Antibodies resistance and extended hospitalization is expected to propel the growth of hospital acquired disease testing in near future
The most common nosocomial infections across the globe are the surgical wounds, urinary tract infections, and lower respiratory tract infections. The highest prevalence of these infections occurs in intensive care units, orthopedic, and acute surgical ward. Out of the mentioned infections, the urinary tract infections is the most common in the patients dwelling with urinary catheter, due to urethra is located close to the anus, which increases the changes of invasions of bacteria from large intestine into the urinary tracts. Due to these infections, the costs and the antibiotic resistance increases with extended hospitalization, which in turn expected to propel the growth of hospital acquired disease testing market. The popular techniques used for preventions, diagnosis, and testing of hospital acquired diseases are microarray, PCR, and solid phase hybridization.
North America and Europe are expected to dominate the hospital acquired disease testing market owing to encouraging government initiatives, regulatory guidelines and reimbursement scenario. Medicare and private insurance companies are eliminating the reimbursement rate due to high rate of hospital acquired infection (HAI) incidence during 2014 and 2015, adding economic pressures on hospitals to reduce hospital acquired diseases. Ion the other hand, unhygienic conditions and practices in developing and underdeveloped economies is resulting in higher incidences of HAI in these regions. Thus, generating a need for HAI testing in this regions during the forecast period.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/992
The key market players are Diatherix laboratories, Life technologies, Cantel Medical Corporation Meridian Biosciences, Qiagen GmbH, Nordion, Roche, and Cepheid & others.